Dr. Clay Siegall is one of the most important individuals in the fight against cancer. This extraordinary man is the holder of at least 15 patents, and he’s the author of 70 medical publications. Thanks to having a Ph.D in Genetics and a B.S. in Zoology, Siegall is more than qualified for the job at hand. George Washington University and the University of Maryland is where he earned his degrees and this is where his passion for cancer research began. Siegall was already aware of how devastating the disease can be because his father struggled with until it until his unfortunate passing. Cancer treatment in those days was brutal on the human body and Siegall set out on a mission to destroy the illness for the greater good of society.
Seattle Genetics is the good doctor’s weapon of choice, and it is one of the leading biotech cancer research organizations in the world. Located in Bothell, Washington, this organization specializes in the commercialization and the development of cancer fighting medications. Antibody-based therapies are produced in abundance here thanks to the wide array of advanced technological features. ADCETRIS, the company’s premier drug, is now been used in up to 65 different countries around the world. This comes via multiple-strategic license deals with major pharmaceutical companies like GlaxoSmithKline, Genentech and Pfizer. Siegall has great business-savvy sense in which he has implemented into the organization’s blueprint. Seattle Genetics didn’t become profitable until after receiving its IPO. As of today, ADCETRIS has brought in over $350 million in profits.
Drug development, scientific innovation and rigorous research are the main principles here. With such consistent success, Seattle Genetics has up to 20 more advanced medications in its pipeline that will be released in the future. What more could anyone ever ask for? All in all, Dr. Clay Siegall has never let his success go to his head. He has a heart of gold and there numerous patients that are willing to testify on his life-saving results.